REGENXBIO is no longer a three-franchise late-stage gene therapy story. The August clinical hold on RGX-121, the Hunter syndrome candidate, parked the nearest rare-disease filing and left the equity hanging on two remaining shots: a Duchenne muscular dystrophy biologics license application for RGX-202, and fourth-quarter pivotal data from the AbbVie-partnered retinal program sura-vec. That is a narrower book than the second-quarter narrative implied, and the market has already marked the Hunter franchise down.
The June quarter's profit was a collaboration event, not a commercial one. License and royalty revenue absorbed a $100 million AbbVie milestone tied to first dosing in the NAAVIGATE diabetic retinopathy study, while Zolgensma royalties faded after United States patents expired in January. Cash at quarter-end was thin enough that the subsequent milestone receipt and a $108 million follow-on were what actually rebuilt the runway into late 2027. Underlying spend stayed in the same neighborhood as a year earlier.
The open question is whether Duchenne and wet AMD can re-rate a company that just lost its nearest filing. Does the RGX-202 package hold up under accelerated review, and do ATMOSPHERE and ASCENT clear a non-inferiority bar against chronic anti-VEGF injections?